
    
      This study examines the effects of IONIS-HBVRx or placebo (3:1 randomization) administered
      subcutaneously to treatment-na√Øve patients who are chronically infected with HBV and the
      effects of subsequent nucleos(t)ide analogue treatment on these patients.
    
  